We surmised understanding AIS would uncover insights into potential tumor-suppressive and resistance mechanisms and provide new avenues for future therapeutic exploitation targeting PI3K/AKT/mTORC1-driven cancers. The gene discussed is PIK3CA; the disease is cancer.